[go: up one dir, main page]

WO2001013958A3 - Conjugues de medicaments et leurs procedes de preparation - Google Patents

Conjugues de medicaments et leurs procedes de preparation Download PDF

Info

Publication number
WO2001013958A3
WO2001013958A3 PCT/US2000/023593 US0023593W WO0113958A3 WO 2001013958 A3 WO2001013958 A3 WO 2001013958A3 US 0023593 W US0023593 W US 0023593W WO 0113958 A3 WO0113958 A3 WO 0113958A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacophore
methods
designing
drug conjugates
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/023593
Other languages
English (en)
Other versions
WO2001013958A2 (fr
Inventor
Sydney Brenner
Philip Goelet
Joseph Stackhouse
Steven W Millward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002382202A priority Critical patent/CA2382202A1/fr
Priority to AU70824/00A priority patent/AU7082400A/en
Priority to EP00959512A priority patent/EP1212096A2/fr
Priority to JP2001518093A priority patent/JP2003507439A/ja
Publication of WO2001013958A2 publication Critical patent/WO2001013958A2/fr
Publication of WO2001013958A3 publication Critical patent/WO2001013958A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des conjugués de médicaments et leurs procédés de préparation. Un des modes de réalisation de cette invention concerne un procédé de préparation des conjugués VLP (vecteur-liant-pharmacophore) pouvant être généralement appliqué à une grande variété de vecteurs, liants, et pharmacophores. En outre, cette invention concerne un procédé d'amélioration de l'administration d'un pharmacophore à un patient, ainsi qu'un procédé d'amélioration de l'efficacité thérapeutique d'un pharmacophore et un procédé de réduction de la toxicité d'un pharmacophore. Par ailleurs, cette invention concerne un procédé d'augmentation de la concentration d'un pharmacophore dans une cellule.
PCT/US2000/023593 1999-08-26 2000-08-28 Conjugues de medicaments et leurs procedes de preparation Ceased WO2001013958A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002382202A CA2382202A1 (fr) 1999-08-26 2000-08-28 Conjugues de medicaments et leurs procedes de preparation
AU70824/00A AU7082400A (en) 1999-08-26 2000-08-28 Drug conjugates and methods of designing the same
EP00959512A EP1212096A2 (fr) 1999-08-26 2000-08-28 Conjugues de medicaments et leurs procedes de preparation
JP2001518093A JP2003507439A (ja) 1999-08-26 2000-08-28 薬物コンジュゲートおよびその設計方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15076599P 1999-08-26 1999-08-26
US15089499P 1999-08-26 1999-08-26
US60/150,765 1999-08-26
US60/150,894 1999-08-26
US18441200P 2000-02-23 2000-02-23
US18441100P 2000-02-23 2000-02-23
US60/184,411 2000-02-23
US60/184,412 2000-02-23

Publications (2)

Publication Number Publication Date
WO2001013958A2 WO2001013958A2 (fr) 2001-03-01
WO2001013958A3 true WO2001013958A3 (fr) 2002-01-31

Family

ID=27495944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023593 Ceased WO2001013958A2 (fr) 1999-08-26 2000-08-28 Conjugues de medicaments et leurs procedes de preparation

Country Status (5)

Country Link
EP (1) EP1212096A2 (fr)
JP (1) JP2003507439A (fr)
AU (1) AU7082400A (fr)
CA (1) CA2382202A1 (fr)
WO (1) WO2001013958A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006170B1 (ru) 2000-07-07 2005-10-27 Трастис Оф Тафтс Коллидж Замещенные соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния субъекта
JP2005526754A (ja) * 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
KR20090083334A (ko) 2006-09-15 2009-08-03 엔존 파마슈티컬즈, 인코포레이티드 방해된 에스테르 기재 생분해성 링커를 갖는 폴리알킬렌 옥시드
US8110559B2 (en) 2006-09-15 2012-02-07 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
MX2009002859A (es) * 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
CN102993116A (zh) * 2012-12-04 2013-03-27 常州大学 一种苯并噁嗪类激动剂的制备方法
CN110963946B (zh) * 2019-12-12 2022-03-11 万华化学集团股份有限公司 一种甲基牛磺酸钠的制备方法
CN111549071A (zh) * 2020-05-15 2020-08-18 乾元康安(苏州)生物科技有限公司 生产蛋白药物偶联物的药物毒性耐受生产细胞株的构建方法及其应用
KR102604462B1 (ko) * 2021-03-08 2023-11-22 비엔제이바이오파마 주식회사 약물 설계 방법 및 이를 이용한 디바이스
CN117624189B (zh) * 2023-11-24 2025-11-11 上海馨远医药科技有限公司 一种6-氧杂-3-氮杂双环[3.1.1]庚烷盐酸盐的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416016A (en) * 1989-04-03 1995-05-16 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416016A (en) * 1989-04-03 1995-05-16 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5635382A (en) * 1989-04-03 1997-06-03 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARCHAND-BRYNAERT J ET AL: "Design and Synthesis of a Bifunctional Label for Selection of beta-Lactamase displayed on Filamentous Bacteriophage by Catalytic Activity", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 52, no. 15, 8 April 1996 (1996-04-08), pages 5591 - 5606, XP004104212, ISSN: 0040-4020 *

Also Published As

Publication number Publication date
WO2001013958A2 (fr) 2001-03-01
AU7082400A (en) 2001-03-19
JP2003507439A (ja) 2003-02-25
CA2382202A1 (fr) 2001-03-01
EP1212096A2 (fr) 2002-06-12

Similar Documents

Publication Publication Date Title
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
HK1046527A1 (zh) 金剛烷衍生物
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2001095899A8 (fr) Compositions pharmaceutiques renfermant des derives de cannabidiol
WO2003028657A3 (fr) Compositions pour therapie genique orale et procedes d'utilisation associes
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
WO2005011653A3 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
WO2003024387A3 (fr) Methode et composition pharmaceutique destinees au traitement d'inflammations
WO2005056524A3 (fr) Agents therapeutiques pour traitement de la douleur
WO2002056912A3 (fr) Methode de traitement du cancer
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2005011655A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
EP1426375A3 (fr) Dérivés analgétiques de spiroindole
AU2002341558A1 (en) Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
WO2001092283A3 (fr) Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie
MXPA03010761A (es) Combinaciones farmaceuticas.
WO2001013958A3 (fr) Conjugues de medicaments et leurs procedes de preparation
WO2002026191A3 (fr) Procedes, compositions et dispositifs utilisant des cellules/capsules urticantes pour administrer un agent therapeutique ou cosmetique dans un tissu
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
WO2003094842A3 (fr) Conjugues comprenant un medicament agissant sur le systeme nerveux central, lequel medicament est lie a un acide glucuronique ou a une glucosamine par l'intermediaire d'une liaison amide, et utilisations correspondantes
WO2003018535A3 (fr) Nouvelles aminobenzophenones
WO2002102318A3 (fr) Medicaments a base d'egline c utilises dans le traitement de maladies
EP1270015A3 (fr) Un complexe de OCIF et de polysaccharide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2382202

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 70824/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000959512

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000959512

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000959512

Country of ref document: EP